Psyence Group Inc. (C:PSYG)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Apr 16, 2024 11:01 am ET

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd...

Mar 26, 2024 11:06 am ET

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the "Transaction"), Psyence is pleased to...

Mar 12, 2024 11:15 am ET

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence...

Mar 11, 2024 07:00 am ET

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination of its subsidiary, Psyence Biomedical Ltd ("PBM") (NASDAQ:PBM) with Newcourt Acquisition Corp...

Jan 25, 2024 06:03 pm ET

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is excited to announce the completion of its subsidiary Psyence Biomedical...

Jan 25, 2024 05:17 pm ET

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company. The Business Combination will list...

Jan 16, 2024 07:54 am ET

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd...

Nov 20, 2023 02:38 pm ET

Psyence Group Announces Resignation of Board Member

Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing announced today that Mr. Marvin Singer has resigned from...

Nov 15, 2023 12:35 pm ET

Canadian Investment Regulatory Organization Trade Resumption - PSYG

VANCOUVER, BC, Nov. 15, 2023 /CNW/ - Trading resumes in:

Nov 15, 2023 12:18 pm ET

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special...

Nov 15, 2023 11:52 am ET

Canadian Investment Regulatory Organization Trading Halt - PSYG

VANCOUVER, BC, Nov. 15, 2023 /CNW/ - The following issues have been halted by CIRO:

Oct 30, 2023 11:09 am ET

Psyence Production Expands Capability

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence...

Aug 21, 2023 02:37 pm ET

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a...

Aug 02, 2023 10:34 am ET

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a...

Jul 12, 2023 07:00 am ET

Psyence Group Corporate Update

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its strategic focus areas namely: Psyence Therapeutics and Psyence Production. The Psyence Group develops and...

Jul 11, 2023 07:00 am ET

Psyence Appoints Intellectual Property Expert to Its Board of Directors

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer,...

Apr 03, 2023 02:44 pm ET

Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note

Psyence Group inc. (CSE:PSYG | OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has issued 9,043,038 common...

Mar 23, 2023 07:00 am ET

Psyence Group Announces Cantheon Capital Private Placement

Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that it has entered into a brokered subscription agreement with...

Mar 21, 2023 07:00 am ET

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that its newly incorporated wholly owned Australian subsidiary,...

Jan 24, 2023 07:00 am ET

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has entered into a partnership...

Jan 20, 2023 07:00 am ET

Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”)...

Jan 16, 2023 06:15 pm ET

The Power Play by The Market Herald Releases New Interviews with Danavation, Psyence Group and Mullen Group Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / January 16, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Danavation, Psyence Group and Mullen Group discussing their latest news.

Jan 09, 2023 05:47 pm ET

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition...

Jan 08, 2023 07:00 pm ET

Psyence Signs Letter of Intent with Australian CRO iNGENū

Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced that it has signed a Letter of Intent (LOI) with Contract Research...

Dec 19, 2022 03:05 pm ET

The Power Play by The Market Herald Releases New Interviews with Trillion Energy, Silver Bullet Mines, Clean Air Metals, Mullen Group and Psyence Group Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Trillion Energy, Silver Bullet Mines, Clean Air Metals, Mullen Group and Psyence Group discussing their latest news.

Dec 15, 2022 08:47 am ET

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life...

Dec 14, 2022 09:00 am ET

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche...

Nov 29, 2022 09:37 am ET

GOODMIND™ Available for Sale in the United Kingdom and Europe - Exclusive Distribution Agreement Concluded With This Works

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint...

Nov 10, 2022 07:00 am ET

Psyence Group Announces Strategic Private Placement

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has received subscription...

Oct 03, 2022 02:15 pm ET

The Power Play by The Market Herald Releases New Interviews with Psyence Group, Vertex Resource and Green River Gold Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / October 3, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Psyence Group, Vertex Resource and Green River Gold discussing their latest news.

Sep 29, 2022 07:00 am ET

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000...

Sep 22, 2022 07:00 am ET

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively...

Sep 20, 2022 03:45 pm ET

The Power Play by The Market Herald Releases New Interviews with Psyence Group, Nextech AR, Eloro Resources, and Baselode Energy Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / September 20, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Psyence Group, Nextech AR, Eloro Resources, and Baselode Energy discussing their latest news.

Sep 19, 2022 07:00 am ET

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for...

Sep 07, 2022 11:00 am ET

Psyence Group Announces Amendment and Closing of Previously Announced Private Placement

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce, further to the Company’s press...

Aug 10, 2022 08:22 am ET

The Flowr Corporation Announces Leadership Transition and Changes to Board of Directors

The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) today announced leadership and governance changes with the appointments of Darren Karasiuk to the role of Chief Executive Officer (“CEO”) and Director and the additions of...

Jun 02, 2022 02:45 pm ET

The Power Play by The Market Herald Releases New Interviews with Avrupa Minerals, good natured Products, Hank Payments, Psyence Group, and Empower Clinics

VANCOUVER, BC / ACCESSWIRE / June 2, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Avrupa Minerals, good natured Products, Hank Payments, Psyence Group, and Empower Clinics on their latest news.

Jun 02, 2022 07:00 am ET

Psyence Group Corporate Update

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function. The Psyence...

May 31, 2022 02:49 pm ET

Psyence Taps Another Pharma Exec to Drive its Clinical Program

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the appointment of Dr. Clive...

May 27, 2022 01:00 pm ET

Market Movers. Today’s Top Stock Picks For New & Trending Opportunities

Market Movers. Today's Top Stock Picks For New & Trending Opportunities

Apr 19, 2022 03:45 pm ET

The Power Play by The Market Herald Releases Interviews With Hank Payments, Red Pine Exploration, Affinor Growers, Nextech AR, Star Navigation, and Psyence

VANCOUVER, BC / ACCESSWIRE / April 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Hank Payments, Red Pine Exploration, Affinor Growers, Nextech AR, Star Navigation, and Psyence on their latest news.

Apr 19, 2022 07:00 am ET

Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

Psyence Group Inc (CSE: PSYG | OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a...

Feb 09, 2022 07:00 am ET

Psyence Group Announces DTC Eligibility Approval in the U.S.

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are...

Feb 07, 2022 02:10 pm ET

The Power Play by The Market Herald Releases Interviews With Opawica Explorations, Psyence Group, and C3 Metals

VANCOUVER, BC / ACCESSWIRE / February 7, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Opawica Explorations, Psyence Group, and C3 Metals on their latest news.

Feb 07, 2022 07:00 am ET

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin...

Jan 21, 2022 10:16 am ET

Psyence looks to expand capital market opportunities in the UK and Europe

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is exploring capital market opportunities...

Dec 03, 2021 10:30 am ET

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive...

Dec 02, 2021 05:30 pm ET

Psyence Group Announces Private Placement

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private...

Dec 02, 2021 07:30 am ET

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its joint venture functional...

Nov 26, 2021 05:30 pm ET

Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim...

Nov 26, 2021 11:00 am ET

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to...

Oct 13, 2021 07:30 am ET

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common...

Oct 12, 2021 10:37 am ET

Psyence Group Jamaica Chief Medical Officer Dr. Dingle Spence to Headline Two Conferences on Psychedelics

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Dr. Dingle Spence, the Chief Medical Officer...

Sep 28, 2021 08:45 am ET

Pure Extracts and Psyence Group Form Joint Venture for Psychedelic Medicinal Mushroom Extracts

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”) and Psyence Group Inc. (CSE: PSYG) (“Psyence”) are pleased to announce the incorporation of a joint venture company, Pure Psyence Corp....

Sep 28, 2021 07:30 am ET

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) announce the signing of a Joint Venture agreement (the “JV”) “Pure Psyence” for the...

Aug 18, 2021 07:30 am ET

Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products

Jul 07, 2021 07:30 am ET

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

Jun 28, 2021 07:30 am ET

Psyence Group Announces Appointment of New Chief Executive Officer

Jun 17, 2021 07:30 am ET

Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development

Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a public life science biotechnology company pioneering the use of natural psychedelics, is pleased to announce that through its wholly owned Jamaican subsidiary, Psyence Jamaica Limited...

Jun 08, 2021 07:30 am ET

The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited

Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company with a global presence, is pleased to announce the incorporation, and operational commencement, of its wholly owned Jamaican subsidiary, “Psyence...

May 27, 2021 07:30 am ET

Psyence Group Corporate Update

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function. Psyence...

May 03, 2021 09:00 am ET

Pure Extracts Corporate Update

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”) is pleased to provide the following corporate update. We are extremely pleased to report that even though the Covid-19 pandemic continues...

Mar 31, 2021 07:00 am ET

Psyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms and Development of Psilocybin Formulations

Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to...

Mar 05, 2021 07:30 am ET

Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that it has entered into a Service Level Agreement with Singapore-based medical biology, forensic science and product development company Base Pair Global Pte. Ltd....

Mar 04, 2021 07:30 am ET

Psyence Group Launches its Functional Mushroom Brand, “Goodmind”

Psyence Group Inc., a leading platform in naturally derived psychedelic therapy and the development and commercialization of related technologies and products (“Psyence” or “the Company”), is pleased to announce it has launched its functional...

Feb 16, 2021 04:31 pm ET

Canadian Securities Exchange Reports Record Trading Volume and Capital Raised for January 2021

Toronto, Ontario--(Newsfile Corp. - February 16, 2021) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of January 2021, which were highlighted by the highest monthly trading volume in the Exchange's history and a record amount of capital raised by CSE-listed issuers.

Feb 10, 2021 07:30 am ET

Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider to Conduct Observational Study

Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased to announce it has entered into a Research Collaboration Agreement with MycoMeditations Inc (“MycoMeditations”), a leading psilocybin retreat...

Feb 03, 2021 05:15 pm ET

Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being...

Jan 29, 2021 07:30 am ET

Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility

Psyence Group Inc. (“Psyence” or the “Company”) is pleased to announce that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium...

Ad blocking detected

Psyence Group Inc. (C:PSYG)

Business Focus: Biotechnology & Medical Research (NEC)